SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bruce Rosen who wrote (218)5/6/1997 12:10:00 PM
From: Richard Ogier   of 7041
 
There is nothing new in the IBD article. The WSJ article last month said many of the same things (see post #169). For this reason, I expect the stock will again slide before the Phase III results are announced. For example, the following is from the WSJ article:

When Zonagen takes the wraps off a six-month
study of some 900 U.S. men, "I think it will show positive
and statistically significant results," says Harin
Padma-Nathan, an associate professor of urology at the
University of Southern California and director of the Male
Clinic in Santa Monica, Calif., one of the larger centers
participating in the clinical trials.
In Phase III trials, researchers seek to determine the
effectiveness of a drug compared with a placebo in human
patients. Dr. Padma-Nathan says many of his patients who
have elected to go into the "open-label" stage of the study --
in which they are no longer given placebos but the drug itself
-- "have been very happy with the results."

Richard
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News